The Use of DOACs in Pediatrics: Current Therapeutic and Prophylactic Indications, Cardiac Indications, and Real-World Evidence—A Review

Abstract

Based on clinical trials that have been conducted and published in the past decade, direct oral anticoagulants (DOACs) are increasingly being used as an antithrombotic treatment in children with venous thrombotic events and to prevent thrombotic events in children at risk. In this review, current indications and standards for the initiation of DOACs in children are summarized for the treatment of venous thrombotic events and for the primary and secondary prevention in children at risk of developing thromboses based on the published randomized controlled trials (RCT). Similarly, indications for DOACs in children with underlying cardiac disease are portrayed based on RCT findings. Lastly, available real-world data are reviewed for the use of DOACs in pediatric patients with a focus on patients at higher risk of both thrombosis and bleeding who were primarily excluded from the RCTs. DOACs contribute largely to the evolving individualization of care of thrombotic events in children, but at-risk patient populations remain underrepresented regarding DOAC experience, such as preterm infants, and children with severe renal or hepatic disease. Real-world data from observational studies and registries will continue to be necessary to establish DOACs' effectiveness and safety in children in everyday clinical use.

Keywords

DOAC - pediatrics - heart disease - VTE treatment - thromboprophylaxis

Publication History

Received: 06 November 2024

Accepted: 25 November 2024

Article published online:
19 February 2025

• References

• 1 Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics 2009; 124 (04) 1001-1008
• 2 O'Brien SH, Stanek JR, Witmer CM, Raffini L. the continued rise of venous thromboembolism across US children's hospitals. Pediatrics 2022; 149 (03) e2021054649
• 3 Monagle P, Chan AKC, Goldenberg NA. et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e737S-e801S
• 4 Monagle P, Cuello CA, Augustine C. et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv 2018; 2 (22) 3292-3316
• 5 Male C, Lensing AWA, Palumbo JS. et al; EINSTEIN-Jr Phase 3 Investigators. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol 2020; 7 (01) e18-e27
• 6 Halton J, Brandão LR, Luciani M. et al; DIVERSITY Trial Investigators. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol 2021; 8 (01) e22-e33
• 7 Brandão LR, Albisetti M, Halton J. et al; DIVERSITY Study Investigators. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood 2020; 135 (07) 491-504
• 8 Connor P, Sánchez van Kammen M, Lensing AWA. et al. Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood Adv 2020; 4 (24) 6250-6258
• 9 McCrindle BW, Michelson AD, Van Bergen AH. et al; UNIVERSE Study Investigators*. Thromboprophylaxis for children post-Fontan procedure: insights from the UNIVERSE study. J Am Heart Assoc 2021; 10 (22) e021765
• 10 Portman MA, Jacobs JP, Newburger JW. et al; ENNOBLE-ATE Trial Investigators. Edoxaban for thromboembolism prevention in pediatric patients with cardiac disease. J Am Coll Cardiol 2022; 80 (24) 2301-2310
• 11 O'Brien SH, Rodriguez V, Lew G. et al; PREVAPIX-ALL Investigators. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial. Lancet Haematol 2024; 11 (01) e27-e37
• 12 Payne RM, Burns KM, Glatz AC. et al. Apixaban for prevention of thromboembolism in pediatric heart disease. J Am Coll Cardiol 2023; 82 (24) 2296-2309
• 13 Kubitza D, Willmann S, Becka M. et al. Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study. Thromb J 2018; 16: 31
• 14 Monagle P, Lensing AWA, Thelen K. et al; EINSTEIN-Jr Phase 2 Investigators. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematol 2019; 6 (10) e500-e509
• 15 Thom K, Lensing AWA, Nurmeev I. et al. Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). Blood Adv 2020; 4 (19) 4632-4639
• 16 Palumbo JS, Lensing AWA, Brandão LR. et al. Anticoagulation in pediatric cancer-associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr. Blood Adv 2022; 6 (22) 5821-5828
• 17 Bosch A, Albisetti M. Adverse events of DOACs in children. Front Pediatr 2022; 10: 932085
• 18 Dietrich K, Stang L, van Ryn J, Mitchell LG. Assessing the anticoagulant effect of dabigatran in children: an in vitro study. Thromb Res 2015; 135 (04) 630-635
• 19 Halton JML, Lehr T, Cronin L. et al. Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open-label phase IIa study. Thromb Haemost 2016; 116 (03) 461-471
• 20 Halton JML, Picard AC, Harper R. et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of dabigatran etexilate oral liquid formulation in infants with venous thromboembolism. Thromb Haemost 2017; 117 (11) 2168-2175
• 21 Halton JML, Albisetti M, Biss B. et al. Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability. J Thromb Haemost 2017; 15 (11) 2147-2157
• 22 Brandão LR, Tartakovsky I, Albisetti M. et al. Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia. Blood Adv 2022; 6 (22) 5908-5923
• 23 Albisetti M, Tartakovsky I, Halton J. et al; Study Investigators. Dabigatran for treatment and secondary prevention of venous thromboembolism in pediatric congenital heart disease. J Am Heart Assoc 2024; 13 (04) e028957
• 24 Male C. Anticoagulation in pediatric patients. Hamostaseologie 2022; 42 (01) 46-53
• 25 Bytzer P, Connolly SJ, Yang S. et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol 2013; 11 (03) 246-52.e1 , 5
• 26 Merali SJ, Byon W, Patel YT. et al. Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder. CPT Pharmacometrics Syst Pharmacol 2023; 12 (04) 500-512
• 27 Manlhiot C, Menjak IB, Brandão LR. et al. Risk, clinical features, and outcomes of thrombosis associated with pediatric cardiac surgery. Circulation 2011; 124 (14) 1511-1519
• 28 Abdelghani E, Cua CL, Giver J, Rodriguez V. Thrombosis prevention and anticoagulation management in the pediatric patient with congenital heart disease. Cardiol Ther 2021; 10 (02) 325-348
• 29 Giglia TM, Massicotte MP, Tweddell JS. et al; American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, and Stroke Council. Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. Circulation 2013; 128 (24) 2622-2703
• 30 Guan C, Guo L, Liang S. Systematic review of randomized clinical trials on direct oral anticoagulants in pediatric heart diseases. Clin Appl Thromb Hemost 2024; 30: 10 760296241271974
• 31 Betensky M, Monagle P, Male C, Goldenberg NA. What did we learn (and did not learn) from the pediatric direct oral anticoagulant trials, and how might we better design pediatric anticoagulant trials in the future?. Res Pract Thromb Haemost 2023; 7 (03) 100140
• 32 Valenti GG, Sabo C, Hyde M, Rajpurkar M. Real-world experience of direct oral anticoagulant use in a single pediatric center. Pediatr Blood Cancer 2024; 71 (05) e30926
• 33 Corrales-Medina FF, Raffini L, Recht M, Santos J, Thornburg CD, Davila J. Direct oral anticoagulants in pediatric venous thromboembolism: experience in specialized pediatric hemostasis centers in the United States. Res Pract Thromb Haemost 2022; 7 (01) 100001
• 34 Hassan E, Motwani J. Real world experience of efficacy and safety of rivaroxaban in paediatric venous thromboembolism. Thromb Res 2023; 221: 92-96
• 35 Hou W, Kong J, Liu L. et al. Incidence of acute deep vein thrombosis in pediatric and adolescent orthopedic trauma hospitalized patients and effect of rivaroxaban treatment. Injury 2024; 55 (08) 111710
• 36 Vander Pluym C, Esteso P, Ankola A. et al. Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease. J Thromb Haemost 2023; 21 (06) 1601-1609
• 37 Kobayashi RL, Cetatoiu MA, Esteso P. et al. Apixaban anticoagulation in children and young adults supported with the HeartMate 3 ventricular assist device. ASAIO J 2023; 69 (06) e267-e269
• 38 Benvenuto V, Hartje-Dunn C, Vo L. et al. Use of apixaban in children awaiting heart transplantation. Pediatr Transplant 2024; 28 (01) e14632
• 39 Adkins K, Williams RJ, Esteso P. et al. Real-world use and outcomes of apixaban for early post-surgical Fontan thromboprophylaxis. Pediatr Cardiol 2024;
• 40 Sagiv E, Newland DM, Slee A, Olson AK, Portman MA. Real-world experience with edoxaban for anticoagulation in children at risk for coronary artery thrombosis. Cardiol Young 2024; 34 (04) 870-875
• 41 Barg AA, Kenet G. Cancer associated thrombosis in pediatric patients. Best Pract Res Clin Haematol 2022; 35 (01) 101352
• 42 Sultan N, Pelland-Marcotte MC, Remy M. et al. Real-world data of the use of rivaroxaban in pediatric patients with hematologic malignancies. Leuk Lymphoma 2024; 65 (04) 538-540
• 43 Raghavan N, Frost CE, Yu Z. et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009; 37 (01) 74-81
• 44 Ogata K, Mendell-Harary J, Tachibana M. et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010; 50 (07) 743-753
• 45 Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014; 53 (01) 1-16
• 46 Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36 (02) 386-399
• 47 Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64 (03) 292-303
• 48 Posch F, Ay C, Stöger H, Kreutz R, Beyer-Westendorf J. Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease. Res Pract Thromb Haemost 2019; 3 (02) 207-216
• 49 Elenjickal EJ, Travlos CK, Marques P, Mavrakanas TA. Anticoagulation in patients with chronic kidney disease. Am J Nephrol 2024; 55 (02) 146-164
• 50 Carlin S, Cuker A, Gatt A. et al. Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH. J Thromb Haemost 2024; 22 (09) 2653-2669
• 51 Holzhauer S, Male C, Monagle P, Bordbar M, van Ommen H, Raffini LJ. Validating direct oral anticoagulants (DOAC) for use in children by the Throm-PED Doac Registry of the International Pediatric Thrombosis Network. Blood 2021; 138 (Suppl. 01) 1063
• 52 van Ommen CH, Albisetti M, Bhatt M. et al; Subcommittee on Pediatric, Neonatal Thrombosis, Hemostasis. International pediatric thrombosis network to advance pediatric thrombosis research: communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis. J Thromb Haemost 2021; 19 (04) 1123-1129
• 53 Furman K, Giustini A, Branstetter J, Woods G, Downey LA. A review of the perioperative management of direct oral anticoagulants for pediatric anesthesiologists. Paediatr Anaesth 2024; 34 (12) 1200-1212
• 54 Bhat RV, Young G, Sharathkumar AA. How I treat pediatric venous thromboembolism in the DOAC era. Blood 2024; 143 (05) 389-403
• 55 Kovac M, Ignjatovic V, Orlando C, Bereczky Z, Hunt BJ. The use of direct oral anticoagulants in the secondary prevention of venous thromboembolism in patients with severe thrombophilia: communication from the ISTH SSC Subcommittee on Physiological Anticoagulants and Thrombophilia. J Thromb Haemost 2024; 22 (11) 3322-3329
• 56 Davila J, Cheng D, Raffini L, Thornburg CD, Corrales-Medina FF. Characterizing the use of anticoagulants in children using the American Thrombosis and Hemostasis Network Dataset (ATHNdataset). Thromb Res 2021; 197: 84-87